



(51) International Patent Classification:

C07D 413/06 (2006.01) *C07D 413/12* (2006.01)
A61K 31/42 (2006.01) *C07D 261/08* (2006.01)

(21) International Application Number:

PCT/IB2015/059631

(22) International Filing Date:

15 December 2015 (15.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/092,402 16 December 2014 (16.12.2014) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **FU, Jiping** [CN/US]; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, California 94608 (US). **JIN, Xianming** [US/US]; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, California 94608 (US). **KARUR, Subramanian** [IN/US]; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, California 94608 (US). **LAPOINTE, Guillaume** [CA/US]; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, California 94608 (US). **MADERA, Ann Marie** [US/US]; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, California 94608 (US). **SWEENEY, Zachary Kevin** [US/US]; Novartis Institutes for BioMedical Research Inc., 5300 Chiron Way, Emeryville, 94608 (US).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: ISOXAZOLE HYDROXAMIC ACID COMPOUNDS AS LPXC INHIBITORS



(I)

(57) Abstract: This invention pertains generally to compounds of Formula I as described herein and compositions containing such compounds, as well as methods of using such compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.